Cluster-related physiopathogenic hypothesis as standing points for treatment recommendations
| Cluster (C) | Physiopathogenic hypothesis | Similar EEG/ERP findings | Recommended treatment |
|---|---|---|---|
| 1 | DA hypoactivity in DLPC | Neurodegenerative and developmental disorders | MPH |
| 2 | Perisylvian network hyperexcitability | Spectrum of perisylvian network epilepsies | CBZ |
| 3 | Excite-inhibit imbalance, thalamocortical | Atypical, phantom absences | VAL |
| 4 | Misallocation of attentional resources | Schizophrenia spectrum, other psychoses | RSP |
| 5 | Vascular-metabolic decoupling | Migraine | VAL, TPM |
| 6 | Cortical hyperexcitability | Other mental disorders | Directed psychotherapy |
First two columns, cluster number and most loaded variables for cluster’s membership (from Table 2). Third column a brief description of the physiopathogenic hypothesis related to the cluster and supporting references. Fourth and fifth columns, other disorders with similar EEG/ERP findings. Last column, recommended treatment for each cluster, based on practice guidelines for the disorders hypothetically sharing some physiopathogenic mechanisms. DA: dopamine; EEG/ERP: electroencephalogram/event-related brain potential; MPH: methylphenidate; CBZ: carbamazepine; VAL: valproic acid; RSP: risperidone; TPM: topiramate